Post-Marketing Study Deadlines Urged As House Tackles FDA Safety Effort

FDA should revisit the post-marketing studies that firms have outstanding, eliminate many of them, and set firm deadlines for the remaining trials, academics suggested at a March 22 hearing by the House Energy and Commerce/Oversight and Investigations Subcommittee

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet